Inosine

Inosine – the drug regulating metabolic processes has anti-hypoxemic and antiarrhytmic effect.

Form of release and structure

• Tablets, film coated: round biconvex form, yellow color; a tablet kernel – white or almost white color (in a blister strip packaging on 10 pieces, in a cardboard pack of 1-5 or 10 packagings; in a blister strip packaging on 25 pieces, in a cardboard pack of 1-5 or 10 packagings; on 50 pieces in a polymeric can, in a cardboard pack of 1 bank; on 50 pieces in a glass jar of dark color, in a cardboard pack of 1 bank);
• Tablets, coated: a biconvex form, from yellow-orange till light yellow color, at a section two layers are visible (in a blister strip packaging on 10 pieces, in a cardboard pack of 1, 2, 3, 4 or 5 packagings);
• Solution for intravenous (in/in) introductions: the colourless or slightly painted transparent liquid (on 5 and 10 ml in glass ampoules of neutral color: in a cardboard pack of 10 ampoules; on 5 or 10 pieces in a blister strip packaging, in a cardboard pack 1 or 2 packagings);
• Capsules: No. 1, gelatinous, firm structure, red color, in capsules – white powder (in a blister strip packaging on 10 pieces, in a cardboard pack of 5 packagings).

In 1 tablet, film coated contains:

• Active ingredient: inosine (inosine) – 0,2 g;
• Auxiliary components: lactoses monohydrate, cellulose microcrystallic, коповидон, calcium stearate;
• Structure of a cover: Опадрай II (series 85) (a macrogoal-3350, partially hydrolyzed polyvinyl alcohol, titanium dioxide (E171), a varnish a sunset, aluminum on the basis of dye, yellow (E110), a varnish aluminum on the basis of indigo carmine (E132), a varnish aluminum on the basis of dye quinolinic yellow (E104), talc).

Coated contains in 1 tablet:

• Active ingredient: inosine – 0,2 g;
• Auxiliary components: sugar, potato starch, titanium dioxide, methyl cellulose water-soluble, twin-80, tropeolin O, stearic acid.

For intravenous administration contains in 1 ml of solution:

• Active ingredient: inosine – 0,02 g;
• Auxiliary components: hexamethylenetetramine (methenamin), 1M hydroxide sodium solution, water for injections.

Contains in 1 capsule:

• Active ingredient: inosine – 0,2 g;
• Auxiliary components: potato starch, calcium stearate;
• Structure of a cover: gelatin pharmaceutical, methylparahydroxybenzoate, глицерол, пропилпарагидроксибензоат, titanium dioxide, dye Red charming (E129), sodium lauryl sulfate, the water purified.

Indications to use

Use of Inosine is shown as a part of complex therapy:

• The period after a myocardial infarction;
• Coronary heart disease;
• Disturbance of a heart rhythm against the background of use of cardiac glycosides;
• Myocardial dystrophy;
• Liver diseases: fatty dystrophy, hepatitis, cirrhosis;
• Urokoproporfiriya.

Besides, solution for in/in introductions is appointed at surgery on the isolated kidney for pharmacological protection at the switched-off blood circulation.

Contraindications

• Age up to 18 years;
• Gout;
• Hyperuricemia;
• Period of pregnancy and breastfeeding;
• Individual intolerance of components of drug.

Besides, use of tablets, film coated, is contraindicated to patients at deficit of lactase, a lactose intolerance, glyukozo-galaktozny malabsorption.

With care it is recommended to appoint Inosine sick with a renal failure.

Route of administration and dosage

Tablets, film coated, and tablets, coated
Pill is taken inside to food.

The recommended dosing mode: at the beginning of therapy – on 0,2 g 3-4 times a day, after 2-3 days of treatment (at adequate portability of drug) transfer the patient to reception of 0,4 g 3 times a day. For achievement of therapeutic effect perhaps gradual increase in a dose, but no more than to 2,4 g a day. Course duration – 30-90 days.

For treatment of an urokoproporfiriya appoint 0,2 g 4 times a day within 30-90 days.

Solution for in/in introductions
Solution of Inosine is entered slowly in/in struyno or kapelno. Speed of infusion should not exceed 40-60 drops 1 minute.

For preparation of infusion solution it is necessary to mix solution of drug from 250 ml 0,9% of solution of sodium of chloride or 5% of solution of glucose.

The recommended dosing for in/in drop introductions: an initial dose – 0,2 g (10 ml) of 1 times a day. At good reaction to drug it is possible to raise a dose to 0,4 g (20 ml) 1-2 times a day. A course of treatment – 10-15 days.

The dosing mode for jet introduction:

• Acute disorders of a heart rhythm: one-time introduction in a dose of 0,2-0,4 g (10-20 ml of solution);
• Pharmacological protection of kidneys: one-time introduction in 5-15 minutes prior to blood circulation switching off – 1,2 g (60 ml), then right after recovery of work of a hepatic artery – 0,8 g (40 ml).

Capsules
Capsules are intended for intake to food.

The recommended dosing: an initial dose – on 1 piece 3-4 times a day, at adequate portability of drug within 2-3 days of therapy for achievement of desirable effect a dose it is possible to raise to 2 pieces 3 times a day (1,2 g). The daily dose should not exceed 12 pieces (2,4 g).

At an urokoproporfiriya to the patient appoint 1 piece 4 times a day.

Duration of treatment is 30-90 days.

Side effects

• Allergic reactions: perhaps – a dermahemia, a skin itch;
• Others: seldom – increase in level of content in blood of uric acid, against the background of long therapy – an exacerbation of gout.

Besides, use of tablets and capsules can cause allergic reaction in the form of a small tortoiseshell.

Special instructions

For rendering the emergency help at disturbance of action of the heart it is not recommended to appoint Inosine.

At emergence of a dermahemia immediate drug withdrawal is required.

Use of drug should be accompanied with regular control of level of concentration of uric acid in urine and blood.

Does not influence ability of the patient to control of vehicles and mechanisms.

Medicinal interaction

Effect of inosine as a part of complex therapy increases efficiency of anti-anginal, antiarrhytmic, inotropic medicines.

The accompanying use of immunodepressants (including antithymocyte immunoglobulin, gamma D - глутамил - D - tryptophane, cyclosporine) reduces efficiency of inosine.

Other clinically significant interactions of Inosine it is not established.

Terms and storage conditions

To store in the unavailable to children and protected from light place at a temperature up to 25 °C, tablets and capsules to protect from moisture.

Period of validity: tablets and solution – 3 years, capsules – 2 years.